EU211 / Eutilex - LARVOL DELTA

Phase 1 trial of 4-1BB-based adoptive T-cell therapy targeting human telomerase reverse transcriptase in patients with advanced refractory solid tumors. (PubMed, Cytotherapy) - "The generation of TERTiNTs was feasible and safe and provided an interesting disease control rate in heavily pre-treated cancer patients."

Journal • Metastases • P1 data • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • CD8 • TERT

Eutilex (263050) R&D momentum to grow stronger, corporate value rise (Maekyung Media Group) - "T-cell therapy AppB&T is in phase 1/2 clinical trial for patients with NK/T lymphoma...Patient administration is expected to begin in early 21st, and data is expected to be released in the second half...Researchers' clinical results will be presented at AACR (American Cancer Society) in April 21. WiT&T...is undergoing phase 1 clinical trials for patients with malignant brain tumors. The results are expected to be announced at the ASCO (American Society of Clinical Oncology) held in June 21. In addition, TAST, a next-generation T-cell therapy technology, is scheduled to apply for a phase 1 clinical trial IND in the second half of 21..."

Enrollment status • IND • New P1 trial • P1 data • P1/2 data • Brain Cancer • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma